The biomarker discovery outsourcing services market size has grown rapidly in recent years. It will grow from $16.96 billion in 2025 to $19.74 billion in 2026 at a compound annual growth rate (CAGR) of 16.4%. The growth in the historic period can be attributed to increasing pharmaceutical r&d spending, expansion of personalized medicine research, rising complexity of drug development pipelines, growing use of biomarkers in oncology trials, availability of specialized outsourcing providers.
The biomarker discovery outsourcing services market size is expected to see rapid growth in the next few years. It will grow to $33.94 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, rising demand for early disease detection tools, expansion of biomarker-driven clinical trials, growing use of ai-enabled biomarker analytics, increasing regulatory acceptance of biomarker endpoints. Major trends in the forecast period include increasing adoption of multi-omics biomarker platforms, rising demand for predictive and prognostic biomarkers, growing use of outsourced biomarker validation services, expansion of companion diagnostics development, enhanced focus on clinical trial biomarker integration.
The growing emphasis on personalized medicine is anticipated to drive the expansion of the biomarker discovery outsourcing services market in the coming years. Personalized medicine refers to a healthcare approach that customizes medical treatment according to the unique characteristics of each patient. The rise of personalized medicine is attributed to individual genetic, lifestyle, and environmental factors, leading to more precise healthcare outcomes that enhance patient care and minimize adverse effects. Outsourcing biomarker discovery services supports the progress of personalized medicine by offering customized diagnostic and therapeutic solutions based on patients' specific biological markers. For example, in February 2024, a report by the Personalized Medicine Coalition, a US-based organization, stated that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, compared to six approvals in 2022. The newly approved personalized treatments in 2023 included seven cancer drugs and three for other diseases and conditions. Thus, the increasing focus on personalized medicine is propelling the growth of biomarker discovery outsourcing services.
Major companies operating in the biomarker discovery outsourcing services market are concentrating on developing multiplexed biomarker assays, such as immunoproteomic discovery platforms, to enhance patient outcomes and advance biomarker discovery. An immunoproteomic discovery platform is a specialized system that integrates immunology and proteomics to identify and analyze proteins associated with the immune response. For example, in October 2023, Sengenics Corporation LLC, a Singapore-based precision medicine company, introduced the immunoproteomic discovery platform, a comprehensive protein microarray system for analyzing autoantibodies linked to disease diagnosis and therapeutic intervention. The i-Ome Discovery platform was created to promote immune biomarker discovery and development and assist academic and clinical biopharmaceutical research teams in gaining a better understanding of the dynamic interactions between proteins, the immune system, and disease.
In March 2025, Momentum Biotechnologies, a US-based contract research organization specializing in mass spectrometry-driven drug discovery, acquired OmicScouts GmbH for an undisclosed sum. Through this acquisition, Momentum seeks to broaden its portfolio of well-validated proteomic assays, accelerate workflows for target engagement and biomarker discovery, and expand its geographic footprint into Europe. OmicScouts GmbH is a Germany-based CRO that focuses on mass spectrometry-based proteomics, chemoproteomics, and biomarker research, offering system-wide assays for target identification, drug response biomarkers, and mechanism-of-action studies.
Major companies operating in the biomarker discovery outsourcing services market are Charles River Laboratories International Inc, Evotec SE, WuXi AppTec Co. Ltd, Precision for Medicine Inc, SomaLogic Inc, Metabolon Inc, Caprion Proteomics Inc, Crown Bioscience Inc, Selvita S.A., Frontage Laboratories Inc, BioAgilytix Labs LLC, Discovery Life Sciences LLC, Labcorp Drug Development Inc, Parexel International Corporation, ICON plc, Medpace Inc, Syneos Health Inc, Celerion Inc, Canopy Biosciences LLC, BioIVT LLC, Intertek Group plc, Eurofins Scientific SE.
North America was the largest region in the biomarker discovery outsourcing services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarker discovery outsourcing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biomarker discovery outsourcing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the biomarker discovery outsourcing services market by increasing costs of imported laboratory instruments, reagents, analytical consumables, and advanced diagnostic equipment used across biomarker identification and validation workflows. Research organizations and pharmaceutical companies in North America and Europe are most affected due to dependence on specialized imported technologies, while Asia-Pacific faces higher costs for exporting biomarker services. These tariffs are increasing project costs and extending study timelines. However, they are also encouraging regional laboratory expansion, domestic sourcing of consumables, and localized service delivery models that improve long-term operational resilience.
The biomarker discovery outsourcing services market research report is one of a series of new reports that provides biomarker discovery outsourcing services market statistics, including biomarker discovery outsourcing services industry global market size, regional shares, competitors with a biomarker discovery outsourcing services market share, detailed biomarker discovery outsourcing services market segments, market trends and opportunities, and any further data you may need to thrive in the biomarker discovery outsourcing services industry. This biomarker discovery outsourcing services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Biomarker discovery outsourcing services are specialized offerings provided by external organizations or companies that support the identification, validation, and development of biomarkers. These services promote the progress of personalized medicine by helping uncover biological indicators that can inform diagnosis, prognosis, and treatment decisions customized to individual patients.
The primary types of biomarker discovery outsourcing services include predictive biomarkers, prognostic biomarkers, safety biomarkers, and surrogate endpoints. Predictive biomarkers are biological indicators that help determine which patients are most likely to respond to a particular therapeutic intervention. The discovery process is divided into phases such as biomarker identification, biomarker validation, biomarker profiling, biomarker panel development, and biomarker selection, applied across therapeutic areas like oncology, cardiology, neurology, autoimmune diseases, and more. The end users of these services include pharmaceutical and biotechnology companies.
The biomarker discovery outsourcing services market includes revenues earned by entities through validation and verification studies, clinical sample analysis, bioinformatics, and data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The biomarker discovery outsourcing services market size is expected to see rapid growth in the next few years. It will grow to $33.94 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, rising demand for early disease detection tools, expansion of biomarker-driven clinical trials, growing use of ai-enabled biomarker analytics, increasing regulatory acceptance of biomarker endpoints. Major trends in the forecast period include increasing adoption of multi-omics biomarker platforms, rising demand for predictive and prognostic biomarkers, growing use of outsourced biomarker validation services, expansion of companion diagnostics development, enhanced focus on clinical trial biomarker integration.
The growing emphasis on personalized medicine is anticipated to drive the expansion of the biomarker discovery outsourcing services market in the coming years. Personalized medicine refers to a healthcare approach that customizes medical treatment according to the unique characteristics of each patient. The rise of personalized medicine is attributed to individual genetic, lifestyle, and environmental factors, leading to more precise healthcare outcomes that enhance patient care and minimize adverse effects. Outsourcing biomarker discovery services supports the progress of personalized medicine by offering customized diagnostic and therapeutic solutions based on patients' specific biological markers. For example, in February 2024, a report by the Personalized Medicine Coalition, a US-based organization, stated that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, compared to six approvals in 2022. The newly approved personalized treatments in 2023 included seven cancer drugs and three for other diseases and conditions. Thus, the increasing focus on personalized medicine is propelling the growth of biomarker discovery outsourcing services.
Major companies operating in the biomarker discovery outsourcing services market are concentrating on developing multiplexed biomarker assays, such as immunoproteomic discovery platforms, to enhance patient outcomes and advance biomarker discovery. An immunoproteomic discovery platform is a specialized system that integrates immunology and proteomics to identify and analyze proteins associated with the immune response. For example, in October 2023, Sengenics Corporation LLC, a Singapore-based precision medicine company, introduced the immunoproteomic discovery platform, a comprehensive protein microarray system for analyzing autoantibodies linked to disease diagnosis and therapeutic intervention. The i-Ome Discovery platform was created to promote immune biomarker discovery and development and assist academic and clinical biopharmaceutical research teams in gaining a better understanding of the dynamic interactions between proteins, the immune system, and disease.
In March 2025, Momentum Biotechnologies, a US-based contract research organization specializing in mass spectrometry-driven drug discovery, acquired OmicScouts GmbH for an undisclosed sum. Through this acquisition, Momentum seeks to broaden its portfolio of well-validated proteomic assays, accelerate workflows for target engagement and biomarker discovery, and expand its geographic footprint into Europe. OmicScouts GmbH is a Germany-based CRO that focuses on mass spectrometry-based proteomics, chemoproteomics, and biomarker research, offering system-wide assays for target identification, drug response biomarkers, and mechanism-of-action studies.
Major companies operating in the biomarker discovery outsourcing services market are Charles River Laboratories International Inc, Evotec SE, WuXi AppTec Co. Ltd, Precision for Medicine Inc, SomaLogic Inc, Metabolon Inc, Caprion Proteomics Inc, Crown Bioscience Inc, Selvita S.A., Frontage Laboratories Inc, BioAgilytix Labs LLC, Discovery Life Sciences LLC, Labcorp Drug Development Inc, Parexel International Corporation, ICON plc, Medpace Inc, Syneos Health Inc, Celerion Inc, Canopy Biosciences LLC, BioIVT LLC, Intertek Group plc, Eurofins Scientific SE.
North America was the largest region in the biomarker discovery outsourcing services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarker discovery outsourcing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biomarker discovery outsourcing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the biomarker discovery outsourcing services market by increasing costs of imported laboratory instruments, reagents, analytical consumables, and advanced diagnostic equipment used across biomarker identification and validation workflows. Research organizations and pharmaceutical companies in North America and Europe are most affected due to dependence on specialized imported technologies, while Asia-Pacific faces higher costs for exporting biomarker services. These tariffs are increasing project costs and extending study timelines. However, they are also encouraging regional laboratory expansion, domestic sourcing of consumables, and localized service delivery models that improve long-term operational resilience.
The biomarker discovery outsourcing services market research report is one of a series of new reports that provides biomarker discovery outsourcing services market statistics, including biomarker discovery outsourcing services industry global market size, regional shares, competitors with a biomarker discovery outsourcing services market share, detailed biomarker discovery outsourcing services market segments, market trends and opportunities, and any further data you may need to thrive in the biomarker discovery outsourcing services industry. This biomarker discovery outsourcing services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Biomarker discovery outsourcing services are specialized offerings provided by external organizations or companies that support the identification, validation, and development of biomarkers. These services promote the progress of personalized medicine by helping uncover biological indicators that can inform diagnosis, prognosis, and treatment decisions customized to individual patients.
The primary types of biomarker discovery outsourcing services include predictive biomarkers, prognostic biomarkers, safety biomarkers, and surrogate endpoints. Predictive biomarkers are biological indicators that help determine which patients are most likely to respond to a particular therapeutic intervention. The discovery process is divided into phases such as biomarker identification, biomarker validation, biomarker profiling, biomarker panel development, and biomarker selection, applied across therapeutic areas like oncology, cardiology, neurology, autoimmune diseases, and more. The end users of these services include pharmaceutical and biotechnology companies.
The biomarker discovery outsourcing services market includes revenues earned by entities through validation and verification studies, clinical sample analysis, bioinformatics, and data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Biomarker Discovery Outsourcing Services Market Characteristics
3. Biomarker Discovery Outsourcing Services Market Supply Chain Analysis
4. Global Biomarker Discovery Outsourcing Services Market Trends and Strategies
5. Biomarker Discovery Outsourcing Services Market Analysis of End Use Industries
7. Global Biomarker Discovery Outsourcing Services Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Biomarker Discovery Outsourcing Services Total Addressable Market (TAM) Analysis for the Market
9. Biomarker Discovery Outsourcing Services Market Segmentation
10. Biomarker Discovery Outsourcing Services Market Regional and Country Analysis
11. Asia-Pacific Biomarker Discovery Outsourcing Services Market
12. China Biomarker Discovery Outsourcing Services Market
13. India Biomarker Discovery Outsourcing Services Market
14. Japan Biomarker Discovery Outsourcing Services Market
15. Australia Biomarker Discovery Outsourcing Services Market
16. Indonesia Biomarker Discovery Outsourcing Services Market
17. South Korea Biomarker Discovery Outsourcing Services Market
18. Taiwan Biomarker Discovery Outsourcing Services Market
19. South East Asia Biomarker Discovery Outsourcing Services Market
20. Western Europe Biomarker Discovery Outsourcing Services Market
21. UK Biomarker Discovery Outsourcing Services Market
22. Germany Biomarker Discovery Outsourcing Services Market
23. France Biomarker Discovery Outsourcing Services Market
24. Italy Biomarker Discovery Outsourcing Services Market
25. Spain Biomarker Discovery Outsourcing Services Market
26. Eastern Europe Biomarker Discovery Outsourcing Services Market
27. Russia Biomarker Discovery Outsourcing Services Market
28. North America Biomarker Discovery Outsourcing Services Market
29. USA Biomarker Discovery Outsourcing Services Market
30. Canada Biomarker Discovery Outsourcing Services Market
31. South America Biomarker Discovery Outsourcing Services Market
32. Brazil Biomarker Discovery Outsourcing Services Market
33. Middle East Biomarker Discovery Outsourcing Services Market
34. Africa Biomarker Discovery Outsourcing Services Market
36. Biomarker Discovery Outsourcing Services Market Competitive Landscape and Company Profiles
37. Biomarker Discovery Outsourcing Services Market Other Major and Innovative Companies
40. Biomarker Discovery Outsourcing Services Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Biomarker Discovery Outsourcing Services Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses biomarker discovery outsourcing services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for biomarker discovery outsourcing services? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biomarker discovery outsourcing services market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Predictive Biomarkers; Prognostic Biomarkers; Safety Biomarkers; Surrogate Endpoints2) By Discovery Phase: Biomarker Identification; Biomarker Validation; Biomarker Profiling; Biomarker Panel Development; Biomarker Selection
3) By Therapeutic Area: Oncology; Cardiology; Neurology; Autoimmune Diseases; Other Therapeutic Areas
4) By End Use: Pharmaceutical Companies; Biotechnology Companies
Subsegments:
1) By Predictive Biomarkers: Disease Risk Assessment; Therapy Response Prediction; Personalized Medicine Guidance2) By Prognostic Biomarkers: Disease Progression Prediction; Patient Survival Forecast; Recurrence Risk Assessment
3) By Safety Biomarkers: Toxicity Prediction; Drug Safety Evaluation; Adverse Effect Risk Assessment
4) By Surrogate Endpoints: Clinical Trial Outcome Indicators; Disease Progression Monitoring; Therapy Efficacy Tracking
Companies Mentioned: Charles River Laboratories International Inc; Evotec SE; WuXi AppTec Co. Ltd; Precision for Medicine Inc; SomaLogic Inc; Metabolon Inc; Caprion Proteomics Inc; Crown Bioscience Inc; Selvita S.A.; Frontage Laboratories Inc; BioAgilytix Labs LLC; Discovery Life Sciences LLC; Labcorp Drug Development Inc; Parexel International Corporation; ICON plc; Medpace Inc; Syneos Health Inc; Celerion Inc; Canopy Biosciences LLC; BioIVT LLC; Intertek Group plc; Eurofins Scientific SE
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Biomarker Discovery Outsourcing Services market report include:- Charles River Laboratories International Inc
- Evotec SE
- WuXi AppTec Co. Ltd
- Precision for Medicine Inc
- SomaLogic Inc
- Metabolon Inc
- Caprion Proteomics Inc
- Crown Bioscience Inc
- Selvita S.A.
- Frontage Laboratories Inc
- BioAgilytix Labs LLC
- Discovery Life Sciences LLC
- Labcorp Drug Development Inc
- Parexel International Corporation
- ICON plc
- Medpace Inc
- Syneos Health Inc
- Celerion Inc
- Canopy Biosciences LLC
- BioIVT LLC
- Intertek Group plc
- Eurofins Scientific SE
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 19.74 Billion |
| Forecasted Market Value ( USD | $ 33.94 Billion |
| Compound Annual Growth Rate | 14.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
